JP2005508966A - ヒト１１ＣＢｙ受容体に対する拮抗薬としてのラクタム誘導体 - Google Patents

ヒト１１ＣＢｙ受容体に対する拮抗薬としてのラクタム誘導体 Download PDF

Info

Publication number
JP2005508966A
JP2005508966A JP2003536220A JP2003536220A JP2005508966A JP 2005508966 A JP2005508966 A JP 2005508966A JP 2003536220 A JP2003536220 A JP 2003536220A JP 2003536220 A JP2003536220 A JP 2003536220A JP 2005508966 A JP2005508966 A JP 2005508966A
Authority
JP
Japan
Prior art keywords
formula
compound
group
phenyl
methoxy
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2003536220A
Other languages
English (en)
Japanese (ja)
Other versions
JP2005508966A5 (enExample
Inventor
アームストロング，スラ，アン
ハムプレヒト，ディーター，ウォルフガング
ジョーンズ，マーティン
ウィッティー，デイヴィッド，リチャード
アル−バラザンジ，カマル，エー．
タデイヨン，モハンマド
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
SmithKline Beecham Ltd
Original Assignee
SmithKline Beecham Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by SmithKline Beecham Ltd filed Critical SmithKline Beecham Ltd
Publication of JP2005508966A publication Critical patent/JP2005508966A/ja
Publication of JP2005508966A5 publication Critical patent/JP2005508966A5/ja
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/44—Iso-indoles; Hydrogenated iso-indoles
    • C07D209/48—Iso-indoles; Hydrogenated iso-indoles with oxygen atoms in positions 1 and 3, e.g. phthalimide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C07D239/72—Quinazolines; Hydrogenated quinazolines
    • C07D239/86—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 4
    • C07D239/88—Oxygen atoms
    • C07D239/91—Oxygen atoms with aryl or aralkyl radicals attached in position 2 or 3
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C07D239/72—Quinazolines; Hydrogenated quinazolines
    • C07D239/95—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in positions 2 and 4
    • C07D239/96—Two oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D257/00—Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms
    • C07D257/10—Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms condensed with carbocyclic rings or ring systems
    • C07D257/12—Six-membered rings having four nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Diabetes (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Anesthesiology (AREA)
  • Rheumatology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Pyrrole Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Steroid Compounds (AREA)
  • Indole Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
JP2003536220A 2001-10-15 2002-10-15 ヒト１１ＣＢｙ受容体に対する拮抗薬としてのラクタム誘導体 Pending JP2005508966A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0124627.1A GB0124627D0 (en) 2001-10-15 2001-10-15 Novel compounds
PCT/US2002/032740 WO2003033480A1 (en) 2001-10-15 2002-10-15 Lactam derivatives as antagonists for human 11cby receptors

Publications (2)

Publication Number Publication Date
JP2005508966A true JP2005508966A (ja) 2005-04-07
JP2005508966A5 JP2005508966A5 (enExample) 2006-01-05

Family

ID=9923785

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2003536220A Pending JP2005508966A (ja) 2001-10-15 2002-10-15 ヒト１１ＣＢｙ受容体に対する拮抗薬としてのラクタム誘導体
JP2003536216A Pending JP2005510487A (ja) 2001-10-15 2002-10-15 メラニン凝集ホルモン受容体１としてのピリミジノン類

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2003536216A Pending JP2005510487A (ja) 2001-10-15 2002-10-15 メラニン凝集ホルモン受容体１としてのピリミジノン類

Country Status (21)

Country Link
EP (2) EP1436267B1 (enExample)
JP (2) JP2005508966A (enExample)
KR (2) KR20040045833A (enExample)
CN (2) CN1571774A (enExample)
AT (2) ATE356119T1 (enExample)
BR (2) BR0213242A (enExample)
CA (2) CA2463509A1 (enExample)
CO (2) CO5580778A2 (enExample)
CZ (2) CZ2004499A3 (enExample)
DE (2) DE60218721T2 (enExample)
ES (2) ES2279009T3 (enExample)
GB (1) GB0124627D0 (enExample)
HU (2) HUP0402346A2 (enExample)
IL (2) IL160872A0 (enExample)
MX (2) MXPA04003532A (enExample)
NO (2) NO20041503L (enExample)
NZ (1) NZ531911A (enExample)
PL (2) PL370587A1 (enExample)
RU (1) RU2004110053A (enExample)
WO (2) WO2003033476A1 (enExample)
ZA (2) ZA200402672B (enExample)

Cited By (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2009506117A (ja) * 2005-08-31 2009-02-12 セルジーン・コーポレーション イソインドール−イミド化合物及びそれを含有する組成物及びそれの使用法
JP2009526794A (ja) * 2006-02-15 2009-07-23 サノフィ−アベンティス 新規なアミノアルコール置換アリールチエノピリミジノン、それらの製造方法及び薬剤としてそれらの使用
JP2009539875A (ja) * 2006-06-08 2009-11-19 イーライ リリー アンド カンパニー 新規なｍｃｈ受容体アンタゴニスト
JP2009539876A (ja) * 2006-06-08 2009-11-19 イーライ リリー アンド カンパニー 新規なｍｃｈ受容体アンタゴニスト
WO2012036233A1 (ja) * 2010-09-17 2012-03-22 塩野義製薬株式会社 メラニン凝集ホルモン受容体アンタゴニスト活性を有する縮合へテロ環誘導体
JP5632612B2 (ja) * 2007-12-05 2014-11-26 あすか製薬株式会社 ラクタム化合物又はその塩及びｐｐａｒ活性化剤
JP2019529353A (ja) * 2016-08-12 2019-10-17 バイエル・クロップサイエンス・アクチェンゲゼルシャフト ２−（２−ジアゾニウム−６−置換フェニル）エタノール塩を環化させることによる４−置換２，３−ジヒドロ−１−ベンゾフラン誘導体の製造方法

Families Citing this family (85)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6664273B2 (en) 2001-11-26 2003-12-16 Schering Corporation Piperidine based MCH antagonists for treatment of obesity and CNS disorders
AU2002352878B2 (en) 2001-11-27 2007-11-22 Merck Sharp & Dohme Corp. 2-Aminoquinoline compounds
DE10238865A1 (de) * 2002-08-24 2004-03-11 Boehringer Ingelheim International Gmbh Neue Carbonsäureamid-Verbindungen mit MCH-antagonistischer Wirkung, diese Verbindungen enthaltende Arzneimittel und Verfahren zu ihrer Herstellung
US7351719B2 (en) 2002-10-31 2008-04-01 Boehringer Ingelheim Pharma Gmbh & Co. Kg Amide compounds having MCH-antagonistic activity and medicaments comprising these compounds
US7772188B2 (en) 2003-01-28 2010-08-10 Ironwood Pharmaceuticals, Inc. Methods and compositions for the treatment of gastrointestinal disorders
US20060194871A1 (en) * 2003-04-11 2006-08-31 Barvian Kevin K Heterocyclic mchr1 antagoists
WO2005016928A1 (ja) * 2003-08-15 2005-02-24 Banyu Pharmaceutical Co., Ltd. イミダゾピリジン誘導体
KR100747042B1 (ko) * 2003-08-19 2007-08-07 솔젠트 (주) 신물질６-메틸-３-펜에틸-３,４-디히드로-１ｈ-큐나졸린-２-티온,이의 제조방법 및 이를 유효성분으로 포함하는 미백 효능조성물
JP2007509158A (ja) * 2003-10-23 2007-04-12 グラクソ　グループ　リミテッド 肥満、糖尿病、うつ病及び不安を治療するためのｍｃｈｒ１アンタゴニストとしての３−（４−アミノフェニル）チエノピリミド−４−オン誘導体
US7592373B2 (en) 2003-12-23 2009-09-22 Boehringer Ingelheim International Gmbh Amide compounds with MCH antagonistic activity and medicaments comprising these compounds
BRPI0507629A (pt) * 2004-02-13 2007-07-03 Banyu Pharma Co Ltd composto, antagonista do receptor e agonista inverso do receptor da histamina h3, agente profilático ou terapêutico para uma doença metabólica, uma doença circulatória ou uma doença do sistema nervoso, ou um seu sal farmaceuticamente aceitável
DE102004010893A1 (de) * 2004-03-06 2005-09-22 Boehringer Ingelheim Pharma Gmbh & Co. Kg Neue ß-Ketoamid-Verbindungen mit MCH-antagonistischer Wirkung und diese Verbindungen enthaltende Arzneimittel
US7605176B2 (en) 2004-03-06 2009-10-20 Boehringer Ingelheim International Gmbh β-ketoamide compounds with MCH antagonistic activity
US20080125403A1 (en) 2004-04-02 2008-05-29 Merck & Co., Inc. Method of Treating Men with Metabolic and Anthropometric Disorders
DE102004017934A1 (de) 2004-04-14 2005-11-03 Boehringer Ingelheim Pharma Gmbh & Co. Kg Neue Alkin-Verbindungen mit MCH-antagonistischer Wirkung und diese Verbindungen enthaltende Arzneimittel
US7524862B2 (en) 2004-04-14 2009-04-28 Boehringer Ingelheim International Gmbh Alkyne compounds with MCH antagonistic activity and medicaments comprising these compounds
ATE446962T1 (de) 2004-12-17 2009-11-15 Lilly Co Eli Thiazolopyridinon-derivate als mch- rezeptorantagonisten
CA2597541A1 (en) * 2005-02-14 2006-08-17 Banyu Pharmaceutical Co., Ltd. Crystal of 4(3h)-quinazolinone derivative
EP1876179B1 (en) * 2005-04-28 2015-03-25 Takeda Pharmaceutical Company Limited Thienopyrimidone compounds
WO2007011286A1 (en) * 2005-07-15 2007-01-25 Astrazeneca Ab Therapeutic agents
RU2418803C2 (ru) * 2005-10-19 2011-05-20 Киссеи Фармасьютикал Ко., Лтд. Конденсированное гетероциклическое производное, содержащая его лечебная композиция и ее применение в медицине
US7745447B2 (en) 2005-10-26 2010-06-29 Bristol-Myers Squibb Company Substituted thieno[3,2-D]pyrimidines as non-basic melanin concentrating hormone receptor-1 antagonists
US8618115B2 (en) * 2005-10-26 2013-12-31 Bristol-Myers Squibb Company Substituted thieno[3,2-d]pyrimidinones as MCHR1 antagonists and methods for using them
ES2412007T3 (es) 2005-12-21 2013-07-09 Janssen Pharmaceutica, N.V. Derivados de pirazinona sustituida novedosos para uso en enfermedades mediadas por MCH-1
US7553836B2 (en) * 2006-02-06 2009-06-30 Bristol-Myers Squibb Company Melanin concentrating hormone receptor-1 antagonists
RU2008136898A (ru) * 2006-02-15 2010-03-20 Санофи-Авентис (Fr) Азациклил-замещенные арилдигидроизохинолиноны, способ их получения и их применение в качестве лекарственных средств
AU2007214708A1 (en) * 2006-02-15 2007-08-23 Sanofi-Aventis Novel azacycly-substituted arylthienopyrimidinones, process for their preparation and their use as medicaments
CA2636617A1 (en) 2006-02-15 2007-08-23 Lothar Schwink Novel aminoalcohol-substituted aryldihydroisoquinolinones, process for their preparation and their use as medicaments
WO2007142217A1 (ja) * 2006-06-07 2007-12-13 Banyu Pharmaceutical Co., Ltd. １－フェニルピリドン誘導体
JP2010500300A (ja) 2006-08-08 2010-01-07 サノフィ−アベンティス アリールアミノアリール−アルキル−置換イミダゾリジン−２，４−ジオン、それらの製造法、それらの化合物を含有する薬剤、およびそれらの使用
JP2010501553A (ja) * 2006-08-18 2010-01-21 アストラゼネカ アクチボラグ Ｍｃｈｒ１アンタゴニストとしてのチエノピリミジン−４−オン誘導体およびチエノピリダジン−７−オン誘導体
ES2483866T3 (es) 2006-12-05 2014-08-08 Janssen Pharmaceutica Nv Derivados de diaza-espiro-piridinona sustituidos novedosos para uso en enfermedades mediadas por MCH-1
WO2008076562A1 (en) * 2006-12-14 2008-06-26 Eli Lilly And Company 5- [4- (azetidin-3-yl0xy) -phenyl] -2-phenyl-5h-thiaz0l0 [5,4-c] pyridin-4-0ne derivatives and their use as mch receptor antagonists
WO2008086404A1 (en) 2007-01-10 2008-07-17 Albany Molecular Research, Inc. 5-pyridinone substituted indazoles
US7851622B2 (en) 2007-04-25 2010-12-14 Bristol-Myers Squibb Company Non-basic melanin concentrating hormone receptor-1 antagonists
US8969514B2 (en) 2007-06-04 2015-03-03 Synergy Pharmaceuticals, Inc. Agonists of guanylate cyclase useful for the treatment of hypercholesterolemia, atherosclerosis, coronary heart disease, gallstone, obesity and other cardiovascular diseases
WO2008151257A2 (en) 2007-06-04 2008-12-11 Synergy Pharmaceuticals Inc. Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders
DE102007028925A1 (de) 2007-06-22 2008-12-24 Saltigo Gmbh Verfahren zur Herstellung von 2-Phenoxyacetalen und den daraus korrespondierenden 2-Phenoxycarbaldehyden
CN101861311A (zh) 2007-07-21 2010-10-13 阿尔巴尼分子研究公司 5-吡啶酮取代的吲唑
PE20091928A1 (es) 2008-05-29 2009-12-31 Bristol Myers Squibb Co Tienopirimidinas hidroxisustituidas como antagonistas de receptor-1 de hormona concentradora de melanina no basicos
ES2627848T3 (es) 2008-06-04 2017-07-31 Synergy Pharmaceuticals Inc. Agonistas de la guanilato ciclasa útiles para el tratamiento de trastornos gastrointestinales, inflamación, cáncer y otros trastornos
WO2010003624A2 (en) 2008-07-09 2010-01-14 Sanofi-Aventis Heterocyclic compounds, processes for their preparation, medicaments comprising these compounds, and the use thereof
ES2624828T3 (es) 2008-07-16 2017-07-17 Synergy Pharmaceuticals Inc. Agonistas de la guanilato ciclasa útiles para el tratamiento de trastornos gastrointestinales, inflamación, cáncer y otros
US8410284B2 (en) 2008-10-22 2013-04-02 Merck Sharp & Dohme Corp Cyclic benzimidazole derivatives useful as anti-diabetic agents
WO2010051206A1 (en) 2008-10-31 2010-05-06 Merck Sharp & Dohme Corp. Novel cyclic benzimidazole derivatives useful anti-diabetic agents
WO2010068601A1 (en) 2008-12-08 2010-06-17 Sanofi-Aventis A crystalline heteroaromatic fluoroglycoside hydrate, processes for making, methods of use and pharmaceutical compositions thereof
CA2689707A1 (en) 2009-11-16 2011-05-16 Jean-Simon Diallo Identification of the novel small molecule viral sensitizer vse1 using high-throughput screening
SG178880A1 (en) 2009-08-26 2012-04-27 Sanofi Sa Novel crystalline heteroaromatic fluoroglycoside hydrates, pharmaceuticals comprising these compounds and their use
JP2013520502A (ja) 2010-02-25 2013-06-06 メルク・シャープ・エンド・ドーム・コーポレイション 有用な抗糖尿病薬である新規な環状ベンズイミダゾール誘導体
US9616097B2 (en) 2010-09-15 2017-04-11 Synergy Pharmaceuticals, Inc. Formulations of guanylate cyclase C agonists and methods of use
CA2826649C (en) 2011-02-25 2016-07-26 Merck Sharp & Dohme Corp. Novel cyclic azabenzimidazole derivatives useful as anti-diabetic agents
WO2012120054A1 (de) 2011-03-08 2012-09-13 Sanofi Di- und trisubstituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung
EP2766349B1 (de) 2011-03-08 2016-06-01 Sanofi Mit carbozyklen oder heterozyklen substituierte oxathiazinderivate, verfahren zu deren herstellung, diese verbindungen enthaltende arzneimittel und deren verwendung
EP2683704B1 (de) 2011-03-08 2014-12-17 Sanofi Verzweigte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung
WO2012120056A1 (de) 2011-03-08 2012-09-13 Sanofi Tetrasubstituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung
EP2683703B1 (de) 2011-03-08 2015-05-27 Sanofi Neue substituierte phenyl-oxathiazinderivate, verfahren zu deren herstellung, diese verbindungen enthaltende arzneimittel und deren verwendung
WO2012120055A1 (de) 2011-03-08 2012-09-13 Sanofi Di- und trisubstituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung
EP2683698B1 (de) 2011-03-08 2017-10-04 Sanofi Mit adamantan- oder noradamantan substituierte benzyl-oxathiazinderivate, diese verbindungen enthaltende arzneimittel und deren verwendung
US8846666B2 (en) 2011-03-08 2014-09-30 Sanofi Oxathiazine derivatives which are substituted with benzyl or heteromethylene groups, method for producing them, their use as medicine and drug containing said derivatives and the use thereof
US8809324B2 (en) 2011-03-08 2014-08-19 Sanofi Substituted phenyl-oxathiazine derivatives, method for producing them, drugs containing said compounds and the use thereof
KR101236188B1 (ko) * 2011-03-10 2013-02-22 한국화학연구원 신규한 피롤로피리디논 유도체 및 그의 ｍｃｈ 수용체-1 관련 질환에 대한 치료학적 용도
HUP1100241A3 (en) 2011-05-06 2013-12-30 Richter Gedeon Nyrt Oxetane substituted pyrimidones
UY34171A (es) 2011-07-01 2013-01-31 Gilead Sciences Inc Compuestos heterocíclicos fusionados como moduladores del canal iónico
NO3175985T3 (enExample) 2011-07-01 2018-04-28
US20140045746A1 (en) 2012-08-02 2014-02-13 Merck Sharp & Dohme Corp. Antidiabetic tricyclic compounds
JP2016516004A (ja) 2013-02-22 2016-06-02 メルク・シャープ・アンド・ドーム・コーポレーションＭｅｒｃｋ Ｓｈａｒｐ ＆ Ｄｏｈｍｅ Ｃｏｒｐ． 抗糖尿病二環式化合物
WO2014139388A1 (en) 2013-03-14 2014-09-18 Merck Sharp & Dohme Corp. Novel indole derivatives useful as anti-diabetic agents
EP2968439A2 (en) 2013-03-15 2016-01-20 Synergy Pharmaceuticals Inc. Compositions useful for the treatment of gastrointestinal disorders
US9708367B2 (en) 2013-03-15 2017-07-18 Synergy Pharmaceuticals, Inc. Agonists of guanylate cyclase and their uses
PL3004138T3 (pl) 2013-06-05 2024-07-29 Bausch Health Ireland Limited Ultra-oczyszczeni agoniści peptydowi cyklazy guanylanowej C, sposób ich uzyskiwania i ich zastosowanie
WO2015051496A1 (en) 2013-10-08 2015-04-16 Merck Sharp & Dohme Corp. Antidiabetic tricyclic compounds
WO2015185531A1 (de) 2014-06-05 2015-12-10 Bayer Cropscience Aktiengesellschaft Bicyclische verbindungen als schädlingsbekämpfungsmittel
WO2017112777A1 (en) 2015-12-22 2017-06-29 SHY Therapeutics LLC Compounds for the treatment of cancer and inflammatory disease
KR102537985B1 (ko) 2016-09-12 2023-05-30 인테그랄 헬스 인코퍼레이티드 Gpr120 조정제로서 유용한 단환형 화합물
WO2018049328A1 (en) * 2016-09-12 2018-03-15 Numerate, Inc. Bicyclic compounds useful as gpr120 modulators
WO2018106518A1 (en) 2016-12-06 2018-06-14 Merck Sharp & Dohme Corp. Antidiabetic heterocyclic compounds
WO2018118670A1 (en) 2016-12-20 2018-06-28 Merck Sharp & Dohme Corp. Antidiabetic spirochroman compounds
KR102736865B1 (ko) 2017-06-21 2024-12-03 샤이 테라퓨틱스 엘엘씨 암, 염증성 질환, 신경발달질환 및 섬유증 질환의 치료를 위하여 Ras 수퍼패밀리와 상호작용하는 화합물
WO2019063708A1 (en) 2017-09-29 2019-04-04 Bayer Aktiengesellschaft SUBSTITUTED 3-PHENYLQUINAZOLIN-4 (3H) -ONES AND USES THEREOF
WO2019063704A1 (en) 2017-09-29 2019-04-04 Bayer Aktiengesellschaft SUBSTITUTED 3-PHENYLQUINAZOLIN-4 (3H) -ONES AND USES THEREOF
JP7407461B2 (ja) 2018-12-19 2024-01-04 シャイ・セラピューティクス・エルエルシー がん、炎症性疾患、ｒａｓ病、及び線維性疾患の処置のためのｒａｓスーパーファミリーと相互作用する化合物
CN110563730B (zh) * 2019-07-29 2022-03-25 江苏理工学院 高纯度n10-三氟乙酰蝶酸的制备方法
WO2022047145A1 (en) 2020-08-28 2022-03-03 Arvinas Operations, Inc. Rapidly accelerating fibrosarcoma protein degrading compounds and associated methods of use
CN113651800B (zh) * 2021-09-07 2022-08-19 山东铂源药业股份有限公司 一种甲磺酸奥希替尼的制备方法
EP4584258A1 (en) 2022-09-07 2025-07-16 Arvinas Operations, Inc. Rapidly accelerated fibrosarcoma (raf) degrading compounds and associated methods of use

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL137227B2 (en) * 1984-03-28 1986-05-31 Univ Lodzki Process for preparing novel n-/dialkylaminoalkoxyphenyl/-imides of tetrahydrophtalic acids
WO1997041097A2 (en) * 1996-12-31 1997-11-06 Dr. Reddy's Research Foundation Novel heterocyclic compounds process for their preparation and pharmaceutical compositions containing them and their use in the treatment of diabetes and related diseases
US7115750B1 (en) * 1999-09-20 2006-10-03 Takeda Pharmaceutical Company Limited Melanin concentrating hormone antagonist

Cited By (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2009506117A (ja) * 2005-08-31 2009-02-12 セルジーン・コーポレーション イソインドール−イミド化合物及びそれを含有する組成物及びそれの使用法
JP2009526794A (ja) * 2006-02-15 2009-07-23 サノフィ−アベンティス 新規なアミノアルコール置換アリールチエノピリミジノン、それらの製造方法及び薬剤としてそれらの使用
JP2009539875A (ja) * 2006-06-08 2009-11-19 イーライ リリー アンド カンパニー 新規なｍｃｈ受容体アンタゴニスト
JP2009539876A (ja) * 2006-06-08 2009-11-19 イーライ リリー アンド カンパニー 新規なｍｃｈ受容体アンタゴニスト
JP5632612B2 (ja) * 2007-12-05 2014-11-26 あすか製薬株式会社 ラクタム化合物又はその塩及びｐｐａｒ活性化剤
WO2012036233A1 (ja) * 2010-09-17 2012-03-22 塩野義製薬株式会社 メラニン凝集ホルモン受容体アンタゴニスト活性を有する縮合へテロ環誘導体
JP2019529353A (ja) * 2016-08-12 2019-10-17 バイエル・クロップサイエンス・アクチェンゲゼルシャフト ２−（２−ジアゾニウム−６−置換フェニル）エタノール塩を環化させることによる４−置換２，３−ジヒドロ−１−ベンゾフラン誘導体の製造方法
JP6998937B2 (ja) 2016-08-12 2022-01-18 バイエル・クロップサイエンス・アクチェンゲゼルシャフト ２－（２－ジアゾニウム－６－置換フェニル）エタノール塩を環化させることによる４－置換２，３－ジヒドロ－１－ベンゾフラン誘導体の製造方法

Also Published As

Publication number Publication date
HUP0402335A3 (en) 2006-02-28
DE60217147D1 (de) 2007-02-08
PL370587A1 (en) 2005-05-30
BR0213040A (pt) 2004-10-05
EP1442025A1 (en) 2004-08-04
CZ2004498A3 (cs) 2004-07-14
KR20050043724A (ko) 2005-05-11
MXPA04003534A (es) 2004-07-22
HUP0402335A2 (hu) 2005-02-28
CA2463509A1 (en) 2003-04-24
MXPA04003532A (es) 2004-07-22
RU2004110053A (ru) 2005-10-20
DE60218721D1 (en) 2007-04-19
NZ531911A (en) 2004-11-26
CO5580778A2 (es) 2005-11-30
CO5580779A2 (es) 2005-11-30
EP1442025B1 (en) 2007-03-07
EP1436267A1 (en) 2004-07-14
BR0213242A (pt) 2004-09-28
WO2003033476A1 (en) 2003-04-24
CN1571774A (zh) 2005-01-26
HUP0402346A2 (hu) 2005-02-28
DE60218721T2 (de) 2007-11-15
DE60217147T2 (de) 2007-10-31
CA2463508A1 (en) 2003-04-24
NO20041503L (no) 2004-05-13
CN1596247A (zh) 2005-03-16
ZA200402672B (en) 2005-04-05
NO20041504L (no) 2004-05-13
KR20040045833A (ko) 2004-06-02
IL160872A0 (en) 2004-08-31
ES2283647T3 (es) 2007-11-01
ZA200402814B (en) 2005-04-13
JP2005510487A (ja) 2005-04-21
WO2003033480A1 (en) 2003-04-24
CZ2004499A3 (cs) 2004-08-18
GB0124627D0 (en) 2001-12-05
ES2279009T3 (es) 2007-08-16
IL161074A0 (en) 2004-08-31
ATE356119T1 (de) 2007-03-15
ATE349434T1 (de) 2007-01-15
EP1436267B1 (en) 2006-12-27
PL370138A1 (en) 2005-05-16

Similar Documents

Publication Publication Date Title
EP1436267B1 (en) Lactam derivatives as antagonists for human 11cby receptors
CA2059363C (en) Benzo¬5,6|cyclohepta¬1,2-b|pyridine derivatives and antiallergic agents comprising same
CN101454328A (zh) 新的mch受体拮抗剂
KR20050085691A (ko) Ｃｂ-1 리간드로서 4,5-디아릴티아졸 유도체
KR20050086931A (ko) 1,5-디아릴-피롤-3-카르복사미드 유도체 및 이의카나비노이드 수용체 조절제로서의 용도
WO2003068749A1 (en) Vanilloid receptor modulators
US20050090496A1 (en) Sulphonyl compounds with 5-ht6 receptor affinity
CA2667372A1 (en) 1,5-diphenyl-3-benzylamino-1,5-dihydropyrrolidin-2-one as cb1 receptor modulators
US20060287321A1 (en) Novel Lactam Derivatives
US6693197B2 (en) Process for the synthesis of derivatives of 2,3-dihydro-1,4-dioxino- [2,3-f] quinoline
JPWO2000050408A1 (ja) ピリダジン−３−オン誘導体及びこれを含有する医薬
CN112888480A (zh) 用于治疗和预防乙型肝炎病毒疾病的新型三环化合物
JP2007511570A (ja) 不適切なａｌｋ５に関連する疾患を治療するための１−アミノ−イソキノリン誘導体
US6369060B1 (en) Indoline derivatives useful as 5-HT-2C receptor antagonists
JP2003231633A (ja) 医薬組成物
AU2002335005A1 (en) Lactam derivatives as antagonists for human 11CBy receptors
US4644064A (en) 1,2-benzisoxazoloxyethylamines and intermediates for the preparation thereof
WO1998052943A1 (en) Indoline derivatives as 5ht2c receptor antagonists
US5500442A (en) Cyclobut-3-ene-1,2-dione derivatives as smooth muscle relaxants
SK131193A3 (en) Heterocyclic compounds with antiasthmatic/antialergic, antiinflammatic positive inotropic and blood pressure lowering effect
US20070185119A1 (en) Therapeutic agents II
HK40053680A (en) Novel tricyclic compounds for the treatment and prophylaxis of hepatitis b virus disease

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20050707

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20050707

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A132

Effective date: 20090310

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20090811